Drug intelligence / Profile preview

ND-023

Development stage: Unknown
Lead developer: Ono Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ND-023 is a preclinical, multi-specific immuno-oncology monoclonal antibody developed by Numab Therapeutics in collaboration with Ono Pharmaceutical, designed to engage multiple targets within the tumor microenvironment to enhance anti-tumor immune responses in cancer. Although detailed target-level information has not been publicly disclosed, the molecule belongs to Numab’s multispecific antibody platform and is being advanced for the treatment of neoplasms, with partnering and licensing agreements involving Ono Pharmaceutical and Boehringer Ingelheim for development and manufacturing support.[1]

Other names: multi-specific immuno-oncology antibody(Numab/Ono Pharmaceutical)

Beyond the preview

Go deeper on ND-023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ND-023.

Explore the full profile